Table 1.
Patient demographics and baseline characteristics
| Placebo | Mipomersen | |
|---|---|---|
| Demographics | n = 12 | n = 21 |
| Gender (M:F), n (%) | 4 (33):8 (67) | 11 (52):10 (48) |
| Agea (years) | 52 (39–68) | 55 (46–69) |
| BMIa (kg/m2) | 26 (22–29) | 27 (21–32) |
| Metabolic syndrome, n (%) | 8 (67) | 9 (43) |
| FH, n (%) | 8 (67) | 11 (52) |
| DMII, n (%) | 1 (8) | 1 (5) |
| CVD, n (%) | 5 (42) | 7 (33) |
| Lipid-lowering therapy, n (%) | ||
| Any lipid-lowering medication | 6 (50) | 12 (57) |
| Ezetimibe | 3 (25) | 7 (33) |
| Colesevelam | 0 (0) | 2 (10) |
| Ciprofibrate | 1 (8) | 0 (0) |
| Nicotinic acid | 2 (17) | 1 (5) |
| Fish oil or omega-3 triglycerides | 2 (17) | 4 (19) |
| Serum aminotransferase activity (U/L) | ||
| ALTb | 25.0 ± 6.7 | 26.5 ± 11.8 |
| ASTb | 23.8 ± 4.0 | 25.5 ± 11.6 |
M, male; F, female; FH, familial hypercholesterolaemia; DMII, type 2 diabetes; CVD, cardiovascular disease.
aData are expressed as median (min–max).
bData are expressed as mean ± standard deviation.